These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 25537198)
1. Oxicams, a class of nonsteroidal anti-inflammatory drugs and beyond. Xu S; Rouzer CA; Marnett LJ IUBMB Life; 2014 Dec; 66(12):803-11. PubMed ID: 25537198 [TBL] [Abstract][Full Text] [Related]
2. Oxicams bind in a novel mode to the cyclooxygenase active site via a two-water-mediated H-bonding Network. Xu S; Hermanson DJ; Banerjee S; Ghebreselasie K; Clayton GM; Garavito RM; Marnett LJ J Biol Chem; 2014 Mar; 289(10):6799-6808. PubMed ID: 24425867 [TBL] [Abstract][Full Text] [Related]
3. Selective inducible microsomal prostaglandin E(2) synthase-1 (mPGES-1) inhibitors derived from an oxicam template. Wang J; Limburg D; Carter J; Mbalaviele G; Gierse J; Vazquez M Bioorg Med Chem Lett; 2010 Mar; 20(5):1604-9. PubMed ID: 20144869 [TBL] [Abstract][Full Text] [Related]
4. [Possibilities of individual choice of NSAIDs on the example of the oxicam class, taking into account clinical and pharmacological characteristics]. Putilina MV; Teplova NV Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(7):36-41. PubMed ID: 35904290 [TBL] [Abstract][Full Text] [Related]
5. Microsomal prostaglandin E2 synthase: a safer target than cyclooxygenases? Timmers L; Pasterkamp G; de Kleijn DP Mol Interv; 2007 Aug; 7(4):195-9, 180. PubMed ID: 17827439 [TBL] [Abstract][Full Text] [Related]
6. Characterization of microsomal prostaglandin E synthase 1 inhibitors. Korotkova M; Jakobsson PJ Basic Clin Pharmacol Toxicol; 2014 Jan; 114(1):64-9. PubMed ID: 24138533 [TBL] [Abstract][Full Text] [Related]
7. [Development of anti-inflammatory drugs targeted against prostaglandin-related molecules]. Sato T; Nakajima T; Yamano Y Nihon Rinsho; 2010 Oct; 68(10):1835-9. PubMed ID: 20954326 [TBL] [Abstract][Full Text] [Related]
8. Distinction of microsomal prostaglandin E synthase-1 (mPGES-1) inhibition from cyclooxygenase-2 inhibition in cells using a novel, selective mPGES-1 inhibitor. Mbalaviele G; Pauley AM; Shaffer AF; Zweifel BS; Mathialagan S; Mnich SJ; Nemirovskiy OV; Carter J; Gierse JK; Wang JL; Vazquez ML; Moore WM; Masferrer JL Biochem Pharmacol; 2010 May; 79(10):1445-54. PubMed ID: 20067770 [TBL] [Abstract][Full Text] [Related]
9. Enzymatic probing of model lipid membranes: phospholipase A2 activity toward monolayers modified by oxicam NSAIDs. Czapla K; Korchowiec B; Orlof M; Magnieto JR; Rogalska E J Phys Chem B; 2011 Jul; 115(29):9290-8. PubMed ID: 21682312 [TBL] [Abstract][Full Text] [Related]
10. [The selective inhibition of cyclooxygenase isoforms: a new approach to the search for effective and safe nonsteroidal anti-inflammatory drug agents]. Viktorov AP Lik Sprava; 1997; (5):106-11. PubMed ID: 9491713 [TBL] [Abstract][Full Text] [Related]
11. Nonacidic inhibitors of human microsomal prostaglandin synthase 1 (mPGES 1) identified by a multistep virtual screening protocol. Rörsch F; Wobst I; Zettl H; Schubert-Zsilavecz M; Grösch S; Geisslinger G; Schneider G; Proschak E J Med Chem; 2010 Jan; 53(2):911-5. PubMed ID: 20025212 [TBL] [Abstract][Full Text] [Related]
12. MF63 [2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile], a selective microsomal prostaglandin E synthase-1 inhibitor, relieves pyresis and pain in preclinical models of inflammation. Xu D; Rowland SE; Clark P; Giroux A; Côté B; Guiral S; Salem M; Ducharme Y; Friesen RW; Méthot N; Mancini J; Audoly L; Riendeau D J Pharmacol Exp Ther; 2008 Sep; 326(3):754-63. PubMed ID: 18524979 [TBL] [Abstract][Full Text] [Related]
13. Perspective of microsomal prostaglandin E2 synthase-1 as drug target in inflammation-related disorders. Koeberle A; Werz O Biochem Pharmacol; 2015 Nov; 98(1):1-15. PubMed ID: 26123522 [TBL] [Abstract][Full Text] [Related]
14. Toward the management of inflammation: recent developments of mPGES-1 inhibitors. Dallaporta M; Pecchi E; Thirion S; Jean A; Troadec JD Recent Pat CNS Drug Discov; 2010 Jan; 5(1):70-80. PubMed ID: 19751209 [TBL] [Abstract][Full Text] [Related]
15. Synthesis, COX-1/2 inhibition and antioxidant activities of new oxicam analogues designed as potential chemopreventive agents. Szczęśniak-Sięga B; Gębczak K; Gębarowski T; Maniewska J Acta Biochim Pol; 2018; 65(2):199-207. PubMed ID: 29906298 [TBL] [Abstract][Full Text] [Related]
16. Unusual coordinating behavior by three non-steroidal anti-inflammatory drugs from the oxicam family towards copper(II). Synthesis, X-ray structure for copper(II)-isoxicam, -meloxicam and -cinnoxicam-derivative complexes, and cytotoxic activity for a copper(II)-piroxicam complex. Cini R; Tamasi G; Defazio S; Hursthouse MB J Inorg Biochem; 2007 Aug; 101(8):1140-52. PubMed ID: 17592742 [TBL] [Abstract][Full Text] [Related]
17. Modified acidic nonsteroidal anti-inflammatory drugs as dual inhibitors of mPGES-1 and 5-LOX. Elkady M; Nieß R; Schaible AM; Bauer J; Luderer S; Ambrosi G; Werz O; Laufer SA J Med Chem; 2012 Oct; 55(20):8958-62. PubMed ID: 22992107 [TBL] [Abstract][Full Text] [Related]
18. Dual acting anti-inflammatory drugs: a reappraisal. Bertolini A; Ottani A; Sandrini M Pharmacol Res; 2001 Dec; 44(6):437-50. PubMed ID: 11735348 [TBL] [Abstract][Full Text] [Related]
19. Prostaglandin E(2) synthase inhibition as a therapeutic target. Iyer JP; Srivastava PK; Dev R; Dastidar SG; Ray A Expert Opin Ther Targets; 2009 Jul; 13(7):849-65. PubMed ID: 19530988 [TBL] [Abstract][Full Text] [Related]
20. PGE synthase inhibitors as an alternative to COX-2 inhibitors. Jachak SM Curr Opin Investig Drugs; 2007 May; 8(5):411-5. PubMed ID: 17520870 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]